Galderma Group AG
Clinical Trials
295
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (272 trials with phase data)• Click on a phase to view related trials
Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)
- Conditions
- Chronic Pruritus of Unknown Origin
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-20
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 50
- Registration Number
- NCT07074977
- Locations
- 🇺🇸
Galderma Investigational Site (site# 8893), Birmingham, Alabama, United States
🇺🇸Galderma Investigational Site (site# 7075), San Francisco, California, United States
🇺🇸Galderma Investigational Site (site# 8521), Saint Joseph, Missouri, United States
A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine
- Conditions
- Skin Quality Improvement
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 171
- Registration Number
- NCT07047638
A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis
- Conditions
- Systemic Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 162
- Registration Number
- NCT07047690
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
- Conditions
- Prurigo Nodularis
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 600
- Registration Number
- NCT06988618
- Locations
- 🇺🇸
Galderma Investigational Site # 8893, Birmingham, Alabama, United States
🇺🇸Galderma Investigational Site # 7077, Phoenix, Arizona, United States
🇺🇸Galderma Investigational Site # 7060, Phoenix, Arizona, United States
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Conditions
- Atopic Dermatitis
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 1000
- Registration Number
- NCT06988605
- Locations
- 🇺🇸
Galderma Investigational Site - 8893, Birmingham, Alabama, United States
🇺🇸Galdrma Investigational Site - 7077, Phoenix, Arizona, United States
🇺🇸Galderma Investigational Site 7060, Phoenix, Arizona, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 55
- Next